Primary targets of fluoroquinolones in Streptococcus pneumoniae.
about
Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondiiGene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysisFluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in CanadaDual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesisCloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactionsMutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniaeMechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniaeTarget preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteriaBactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.Longitudinal assessment of antipneumococcal susceptibility in the United States.Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Upgrading antibiotic use within a class: tradeoff between resistance and treatment success.Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America.The new fluoroquinolones: A critical reviewIn vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groupsReal-time PCR and high-resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types.In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.Genomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae.Transmission of dapsone-resistant leprosy detected by molecular epidemiological approaches.Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.
P2860
Q28345231-2F35A53B-EDCD-4A6B-AE6B-00C1B5E48F63Q28345923-CC3F370E-2AF0-4B36-82D2-6CD823D3EF0AQ33594174-1AC449C9-5C7A-41A9-A209-502BBC1A1C52Q33663032-4CB625CA-2799-46FF-B117-A1EFA6DB2900Q33770013-FAA7F58F-D244-4E38-93E2-3FC4B5FD3A99Q33770218-88FF0E3A-D6BD-495A-A9EF-FC1E46A110E0Q33980255-9E52D0CD-99F6-4987-9605-EE2DD981711DQ33980747-7EA8D9C2-CF21-4CEF-96ED-224733D9760EQ33980991-6A47BCCB-86B4-49A2-BB7C-767C8B56155EQ33981343-6DC556A5-EE59-4E0D-94ED-4B2BDA4ADD2AQ33981554-6BA9700B-499A-48DA-95AD-43B5CD67CDBFQ33982417-1557B16F-8775-4231-8386-EE6D9C9A2C6EQ33983092-4364A85A-493C-4AF6-9F77-E80FC81EA007Q33983643-2E9A87A8-AE31-4F84-B954-835762E8BE0BQ33983660-27794FF8-0115-4511-92CB-E8ABB8E1A9EDQ34035762-9D11E867-BE73-415B-AC45-28C096A72713Q34104362-2325E712-7F75-4601-B96C-CD4BCB9A726DQ34110932-0A07F3BA-536F-41BA-9CEE-74ED6FC9D287Q34113933-26BBD4C5-FF0B-48E4-9F50-5370785C95C4Q34142238-77690456-552E-4B8F-A788-CB7B045F4255Q34687139-791BD3F6-C580-412D-A155-122AB57597A5Q34721556-FA41A8B8-3F7C-4EF0-A773-C73AFC0538ADQ35026714-A82A7095-1BA7-4860-8BC3-6DFD6A1CE088Q35649595-77DBBE4B-4E28-41BD-AE8A-218E14C8917DQ35758905-66225F56-BBCF-46D5-8128-712E7CCC9763Q35806981-F026A936-3376-48A3-9E6A-766A5DF043DDQ37119995-2F9EA594-BCC8-4E09-9131-B2D79018B564Q37263914-8E49CEE1-268C-49DC-82C1-B55384185E57Q38726760-255CC549-CB16-4CF2-A77D-3DFF619049A3Q39465570-28569F41-1A09-4933-853C-C46478759753Q39471404-CA6A604F-0F6C-4A1B-93BB-6C01A13F46CCQ39472007-C9774ADA-BC76-44E0-86EC-6AA49D511C18Q39472798-3383C6C5-4995-4D10-8D5A-ADFD2642303EQ39475328-27A585A8-C715-48CE-ADB9-10ED7C1C4D37Q39476686-E12EB029-964E-4304-84E0-3BBFB199548BQ39477371-04F6F0DD-7C0E-4BD8-8843-C66899BAEAABQ39478835-787039DF-45EA-4535-92B6-098CD1475FE0Q39537237-45ABF427-0CEC-463B-B313-58FFC8F5E966Q39651028-C1184675-89B3-4611-AF77-88A895426586Q39651301-5D9BBC10-58A3-49FA-901A-4803E1B59852
P2860
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
@en
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
@nl
type
label
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
@en
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
@nl
prefLabel
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
@en
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
@nl
P2860
P356
P1476
Primary targets of fluoroquinolones in Streptococcus pneumoniae
@en
P2093
P2860
P304
P356
10.1128/AAC.43.2.410
P407
P577
1999-02-01T00:00:00Z